Menu Search
Equities

Celon Pharma SA

8RP:STU

Celon Pharma SA

Actions
  • Price (EUR)5.67
  • Today's Change-0.42 / -6.90%
  • Shares traded0.00
  • 1 Year change+75.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Celon Pharma SA grew revenues 11.29% from 194.59m to 216.57m while net income improved from a loss of 39.28m to a smaller loss of 28.12m.
Gross margin70.12%
Net profit margin-21.69%
Operating margin-20.86%
Return on assets-7.79%
Return on equity-9.82%
Return on investment-9.03%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Celon Pharma SA fell by 50.54m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 8.31m. In addition the company used 21.64m on investing activities and also paid 20.59m in financing cash flows.
Cash flow per share0.1617
Price/Cash flow per share169.59
Book value per share9.00
Tangible book value per share8.77
More ▼

Balance sheet in PLNView more

Celon Pharma SA uses little debt in its capital structure as supported by a debt to capital ratio of 3.21%.
Current ratio2.61
Quick ratio2.27
Total debt/total equity0.0332
Total debt/total capital0.0321
More ▼

Growth rates in PLN

SmartText is unavailable
Div yield(5 year avg)0.43%
Div growth rate (5 year)-19.73%
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-51.54
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.